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Calcium and
C-Reactive Protein
Hot Enough to Predict the Future?*
Christian W. Hamm, MD, Holger M. Nef, MD,
Andreas Rolf, MD, Helge Möllmann, MD
Bad Nauheim, Germany
“My interest is in the future, because I am going
to spend the rest of my life there.”
—Charles F. Kettering (1876–1958),
American engineer and inventor of the electric starter (1)
It is very reasonable and most common for a human being
to find out about his or her own future. That is why even
strict scientists are tempted to make use of fortune tellers
and horoscopes. When patients see their physicians, they
expect to receive an answer regarding how long they will live
and what health problems they may face in the future. This
ends frequently in a challenge, because how can one apply
statistics to individual recommendations? Answers such as,
“You have 10 more years to live” appear unreasonable, even
though this may be based on good evidence. Therefore, a
good physician will avoid a direct answer and use surrogates
to please the patient, such as, “Your laboratory result
indicates that you need help.” For this answer, 2 things need
to be known by the physician: how high the risk is and how
the risk can be changed. This applies similarly to primary
prevention of coronary artery disease (CAD).
See page 1455
The classic risk factors for developing CAD are well
established and, today, also known by medical laypersons.
Individuals with no risk factors such as smoking, diabetes,
hypercholesterolemia, or hypertension and no family history
of CAD can easily be given good advice, although up to
20% of patients with a coronary event have none of the
indicators (2). Similarly, subjects with an overt high-risk
profile need no further evaluation, but a clear management.
Our energy should be directed toward the intermediate-risk
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Framingham risk score (FRS), are helpful, but provide only
limited incremental information. More may be expected
from variables that directly reflect the underlying patho-
physiology.
CAD develops very early in life and is usually silent over
decades. Its pathomechanism has been extensively studied
over the last years, and much interest has been focused on
the involvement of calcium. The calcification of the athero-
sclerotic plaque occurs via an active process resembling bone
formation and is controlled by complex enzymatic and
cellular pathways (3). Recently, numerous studies were able
to show the attendance of osteoblast-like cells, transcription
factors, and bone morphogenetic proteins in the process of
calcification. The initiating mechanism of calcification re-
quires apoptosis of smooth muscle cells to generate apopto-
tic bodies that act as nucleating foci of calcification, inflam-
mation, lipoprotein and phospholipid accumulation, and
finally, hydroxyapatite deposition. The dignity of calcifica-
tion has been investigated extensively. However, whether it
is a benign bystander or a truly suspicious finding is so far
unknown. Nevertheless, there is good evidence that mainly
spotty calcification is a feature of vulnerability and is closely
related to plaque rupture, eventually resulting in life-
threatening events. Increasing prevalence of CAD translates
into very large costs to society, which could be attenuated if
better models of prediction of atherosclerosis are available.
Accordingly, many indirect approaches such as the carotid
intima-media thickness and various markers of peripheral
arterial stiffness have been proposed. However, the direct
assessment of coronary plaque burden and the activity of the
process appear more attractive. The tools to achieve this
information are currently best provided by a combination of
imaging modalities and biomarkers.
Biomarkers and Prognosis
A great number of biomarkers have been investigated over
recent years, reflecting different pathophysiologic mecha-
nisms in acute coronary syndromes and in stable angina.
Less well investigated is the role of biomarkers in primary
prevention settings.
The most promising appear to be markers that indicate
the transition of a silent to a vulnerable plaque. Accordingly,
most of the investigated markers reflect inflammation, such
as interleukins, myeloperoxidase, neopterin, matrix metal-
loproteinase (MMP)-9, and monocyte attracting protein
(MCP)-1. Best established is high-sensitivity C-reactive
protein (hsCRP), which is an acute-phase reactant and
therefore rather unspecific for local processes (4). However,
hsCRP can serve as a target for therapy, which is of
paramount importance in translating results to clinical
practice (5).
Many other novel biomarkers reflecting elegantly local
plaque activity and vulnerability, such as growth differenti-
ation factor (GDF)-15 or lipoprotein-associated phospho-
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information in patients with acute coronary syndromes and
stable CAD, but may be less predictive in primary preven-
tion with follow-up over many years (6).
Another approach is to measure markers of myocardial
function, like the B-type natriuretic peptide (BNP) and the
biologically inactive split product N-terminal (NT)-
proBNP, which are already routinely available to evaluate
patients with dyspnea. Both were shown to be good predic-
tors in patients with acute coronary syndromes and stable
CAD (7). Recently, a strong association between BNP and
the severity of coronary atherosclerosis has been demon-
strated. However, BNP does not primarily reflect coronary
plaque burden but may rather indicate myocardial ischemia
even if clinically silent (8,9). Furthermore, so far, no
therapeutic strategy could be identified to influence the
adverse prognosis associated with elevated BNP levels.
Imaging of Plaque Burden
Different strategies have been developed to assess plaque
burden including invasive and noninvasive tools (electron-
beam computed tomography [EBCT], computed tomogra-
phy [CT], magnetic resonance imaging, and positron emis-
sion tomography/CT). The Agatston score as measure of
overall coronary artery calcification (CAC), introduced by
EBCT, has been further developed in the setting of mul-
tislice CT, which has the additional benefit of coronary
angiography with the possibility to image single plaques and
their different compositions. This can be achieved by only
moderate exposure to ionizing radiation, which is generally
in the range of 0.5 to 1.0 mSV, and is therefore rather
negligible.
It could be shown that CAC in addition to the classic risk
factors increases the predictive power for coronary events
(10). However, there remain major concerns related to the
role of calcifications in atherosclerosis, which is still not
completely elucidated. Calcifications grow as atherosclerosis
progresses as a function of aging and may develop toward
stenotic lesions. However, it remains unclear whether cal-
cification stabilizes atheromas or makes them more prone to
rupture. In a comparison of acute and chronic events, acute
events were found to have considerably lower CAC scores
compared with chronic events (63 vs. 906) (11). In contrast,
other evidence shows that spotty calcification and presence
at the shoulders of plaques increase the risk of rupture (12).
This dilemma is nicely reflected in a recent study demon-
strating that lesions of acute coronary syndromes have less
absolute calcium content but more frequently a spotty
calcification pattern (13). Accordingly, a person with little
or even no calcium is not entirely safe from coronary events.
Combination of Biomarkers and Imaging
Risk assessment of CAD with both biomarkers and differ-
ent imaging modalities has distinct shortcomings. However,
combining both approaches may overcome the methods’individual limitations. In this issue of the Journal, Möhlen-
kamp et al. (14) demonstrated that such a combination of
hsCRP and CAC (by EBCT) is able to identify patients at
very high risk for coronary events. A total of 3,966 subjects
of the well-defined, prospective Heinz Nixdorf Recall study,
with known hsCRP and CAC, were included and followed
up for over 5 years (mean 5.1  0.3 years). Both predictors
independently and accurately identified coronary events and
all-cause mortality. Furthermore, net reclassification as a
measure of incremental prognostic information improved
the prediction of coronary events by 10.5% for hsCRP and
23.8% for CAC, respectively.
When introducing a new diagnostic test or a combination
of such, one expects an improved prediction of events. The
ability of a test to make such a prediction is called discrim-
ination. When more than 2 categories of increasing risk are
used, we expect the test to have the same prognostic value
across all categories, an ability called calibration.
There is an ongoing debate about which statistical test
most accurately reflects incremental diagnostic value. The
traditional c-statistic has recently been criticized because of
its limited power to detect and reflect improved prediction.
The net reclassification index as a measure of how many
patients are reclassified into a category that better suits their
outcome and the integrated discrimination index as a
continuous measure of prediction are currently considered
the gold standard of testing risk measure (15). Here, the
authors show improved diagnostic performance with all
aforementioned tests, a thoroughness that underlines the
benefit of their risk score.
The authors also show that their newly introduced score
is well calibrated. This is especially interesting as they
outperform the classic FRS in all risk categories and
reclassify patients in all of the 3 FRS categories in all
possible directions.
Practical Considerations
What practical conclusions arise from these findings? Pa-
tients who are considered to be at high risk for cardiovas-
cular events given an increased level of hsCRP, but other-
wise apparently healthy, have been treated in the JUPITER
(Justification for the Use of statins in Prevention: An
Intervention Trial Evaluating Rosuvastatin) trial with rosu-
vastatin as primary prophylaxis (5). This intervention could
reduce cardiovascular events by one-half over a period of 2
years, suggesting that risk stratification and decision making
according to elevated hsCRP levels can indeed change the
individual’s future significantly. However, these results have
to be challenged in 2 ways: First, we still don’t know
whether the intervention, that is, aggressive lipid lowering
in the absence of overt disease, improves the outcome
independently from elevated hsCRP. Second, a large-scale
genome-wide association-based study found no concor-
dance between the effect on CAD risk of CRP genotypes
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association of CRP with CAD (16).
Likewise, it is unclear what practical implications emerge
from high CAC scores since it is to date not known which
role CAC might play in predicting the vulnerability of
single plaques and, therefore, the immediate, not stochastic,
risk of a single patient.
Furthermore, socioeconomic aspects have to be consid-
ered against the background of limited health care resources.
Given the relatively low event rate reported in the Nixdorf
Recall Study and the likewise low percentage of patients
reclassified into the high-risk group due to hsCRP or CAC
findings, it has to be assumed that the “number needed to
reclassify,” that is, the number of patients that has to
undergo hsCRP measurement and a CT for CAC to predict
1 cardiovascular event, is rather high, and even then we still
have no definite concept as to how to avoid this event. This
assumption is further supported by the fact that more
patients died from cancer than from cardiovascular causes.
Getting back to the future: applying the methods pro-
posed by Möhlenkamp et al. (14) definitely makes us better
medical fortune tellers, but how to translate this knowledge
into a better treatment in order to become better doctors has
yet to be defined.
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